Health Insurance (Pathology Services Table) Amendment Regulations 2009 (No. 1) (Cth)

Text

1 Name of Regulations

2 Commencement

3 Amendment of Health Insurance (Pathology Services Table) Regulations 2008

Schedule 1 Amendments

Health Insurance (Pathology Services Table) Amendment Regulations 2009 (No. 1)¹

Select Legislative Instrument 2009 No. 62

I, QUENTIN BRYCE, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973.

Dated 9 April 2009

QUENTIN BRYCE

Governor-General

By Her Excellency’s Command

NICOLA ROXON

Minister for Health and Ageing

1              Name of Regulations

                These Regulations are the Health Insurance (Pathology Services Table) Amendment Regulations 2009 (No. 1).

2              Commencement

                These Regulations commence on 1 May 2009.

3              Amendment of Health Insurance (Pathology Services Table) Regulations 2008

Schedule 1 amends the Health Insurance (Pathology Services Table) Regulations 2008.

Schedule 1        Amendments

(regulation 3)

[1]           Schedule 1, Part 2, paragraph 13 (7) (b)

substitute

               (b)    more than 1 of the services mentioned in items 73059, 73060, 73061, 73064 and 73065;

[2]           Schedule 1, Part 2, paragraph 25 (4) (a)

after

66539,

insert

66607,

[3]           Schedule 1, Part 2, subrule 25 (5)

after

66551,

insert

66660,

[4]           Schedule 1, Part 2, subrule 25 (5)

omit

, 73314, 73315

[5]           Schedule 1, Part 3, item 66605

substitute

66605 Vitamins — quantitation of vitamins B1, B2, B3, B6 and C in blood, urine or other body fluid (Item is subject to rule 25) 31.15

[6]           Schedule 1, Part 3, after item 66606

insert

66607 Vitamins — quantitation of vitamins A and E in blood, urine or other body fluid (Item is subject to rule 25) 76.27

[7]           Schedule 1, Part 3, item 66638

omit

29.70

insert

49.70

[8]           Schedule 1, Part 3, item 66659

omit

in the equivocal range of the particular method of assay used to determine the level

insert

above the age-related median but below the age-related, method-specific 97.5% reference limit

[9]           Schedule 1, Part 3, after item 66659

insert

66660 Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies above the age‑related, method-specific 97.5% reference limit, but below 10 µg/L (Item is subject to rule 25) 37.80

[10]         Schedule 1, Part 3, after item 66832

insert

66900 Carbon‑labelled urea breath test using oral C‑13 or C‑14 urea, including the measurement of exhaled ¹³CO₂ or ¹⁴CO₂, (except if item 12533 applies) for:    (a)  the confirmation of Helicobactor pylori colonisation; or    (b)  the monitoring of the success of eradication of Helicobactor pylori 78.15

[11]         Schedule 1, Part 3, item 71200

omit

kappa or

insert

kappa and

[12]         Schedule 1, Part 3, item 73049

substitute

73049 Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues — 1 identified site 68.60

[13]         Schedule 1, Part 3, item 73059

omit

73049 and 73051

insert

73049, 73051 and 73062

[14]         Schedule 1, Part 3, item 73060

omit

73049

insert

73049, 73062

[15]         Schedule 1, Part 3, item 73060

omit

4 or more

insert

4 to 6

[16]         Schedule 1, Part 3, item 73061

omit

73049

insert

73049, 73062

[17]         Schedule 1, Part 3, after item 73061

insert

73062	Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues — 2 or more separately identified sites	89.60
73063	Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if an employee of an approved pathology authority also attends the aspiration for confirmation of sample adequacy	100.00
73064	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051 and 73062 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 7 to 10 antibodies (Item is subject to rule 13)	72.20
73065	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051 and 73062 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 11 or more antibodies (Item is subject to rule 13)	89.60

[18]         Schedule 1, Part 3, item 73300

substitute

73300 Detection of mutation of the FMR1 gene if:    (a)  the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMR1 mutation; or    (b)  the patient has a relative with an FMR1 mutation; 1 or more tests 103.10

[19]         Schedule 1, Part 3, item 73314

omit

(Item is subject to rule 25)

[20]         Schedule 1, Part 3, item 73315

omit

, 18A and 25

insert

and 18A

Note

1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See